European Medicines Agency's data protection notice on the study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”

Submitted by Anonymous (not verified) on 16 May 2024 - 10:18

European Medicines Agency's data protection notice on the study of the “Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV- during the Omicron period”

Human medicines European public assessment report (EPAR): Pregabalin Mylan, pregabalin, Date of authorisation: 24/06/2015, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 16 May 2024 - 9:29

Human medicines European public assessment report (EPAR): Pregabalin Mylan, pregabalin, Date of authorisation: 24/06/2015, Revision: 17, Status: Authorised

Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 May 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 May 2024 to 16 May 2024

Submitted by Anonymous (not verified) on 14 May 2024 - 17:00

Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 May 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 May 2024 to 16 May 2024

Human medicines European public assessment report (EPAR): Olanzapine Mylan, olanzapine, Date of authorisation: 06/10/2008, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 14 May 2024 - 13:37

Human medicines European public assessment report (EPAR): Olanzapine Mylan, olanzapine, Date of authorisation: 06/10/2008, Revision: 20, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More